Replies to post #28130 on OncoSec Medical Inc (ONCSQ)

[cameron12x]

That would translate to about $2.50/share at the high end.

But remember timing is everything. The earlier the buyout, the cheaper the buyout price because the buyer then starts to assume more of the risk. The longer big pharma waits, however, the higher the buyout price becomes. A classic case of weighing risk vs. reward.

IF a buyout were to occur by Merck, I'd suggest it "could" happen in Q3 or Q4 of 2015. Other suitors might be lining up in parallel, or afterwards.

But again, all of this is conjecture until proven as fact.

[Jumpinjackas]

Yes, the worst scenario for a developmental biotech is a buy out. I wonder what the best one would be.

Why didn't Merck sign a contract to have rights when they "collaborated" with us for the trial?

Please disregard all this as I think the pps being held down by the MMs and Santa clause.

[Jumpinjackas]

Great insight. The worst case for a developmental biotech is buyout!



I'm sure the MMs know this and are accumulating. Once we present at ASCO then we are going to take off.